Taking the jab (and the chill) out of vaccination

March 13, 2018, James Cook University
The vaccine was effective when administered orally to mice, and theoretically would not require refrigeration. Credit: Romy Bullerjahn

Scientists in Cairns (Australia) and Cardiff (Wales) have taken an important first step towards solving two problems that hinder access to vaccines: they need to be kept cool, and no one likes needles.

In the April edition of the Journal of Clinical Investigation, a team led by Associate Professor John Miles from James Cook University and Cardiff University's Professor Andrew Sewell describe how they engineered a new production platform and built a fully synthetic flu vaccine.

The vaccine protected mice from potentially lethal doses of and also worked on human cells when tested in the laboratory.

"Theoretically, this prototype synthetic vaccine would not require refrigeration and could sit on the shelf for years without going out of date," Professor Sewell said.

"In addition to being expensive, maintaining a cold chain of delivery can be extremely difficult in remote areas of the globe. In hot places without reliable electricity, this can count for the majority of the cost of vaccines, and significant wastage."

Taking the needle out of the equation would also make vaccinations simpler to administer, and a whole lot less frightening.

"To be administered orally, vaccines need to be able to survive the acids and enzymes in our stomachs. A couple - including the - can do this, but most cannot," said Associate Professor Miles, Principal Research Fellow at the Australian Institute of Tropical Health and Medicine.

The team showed the synthetic vaccine was hyper-stable in both stomach and human blood, meaning it could be taken orally. Promisingly, it was effective when administered orally to mice.

To build their synthetic vaccine, the team used D-amino acids. "These are mirror images of the L-amino acids that are the building blocks of all proteins," Associate Professor Miles said. "While L-amino acids are common in nature, D-amino acids are rare. We were attracted to them because they're very stable, meaning these compounds are harder to break down."

After trialing D-Amino acids in various combinations, the researchers selected a version that successfully provoked the immune system's T cells to launch a defensive attack, protecting the mice when they were later given swine flu.

"We were very surprised at how flexible the immune system is in recognizing dangerous targets," Associate Professor Miles said. "It can't actually tell the difference between our antigen and a real-world fragment of swine flu. This suggests you can build vaccines out of anything you want as long as they 'look' like the real thing in three dimensions."

While we might be a long way from taking our vaccines orally and at room-temperature, Associate Professor Miles says this proof-of-concept study shows exciting promise.

"We have some further work to do in making these vaccines work across larger populations and against other bugs and possibly cancer," he said. "But what we have now is a promising platform for synthetic vaccine production. We hope these new concepts and advances will help make a significant contribution to health world-wide."

Explore further: Scientists create world's first synthetic, non-biologic vaccine

Related Stories

Scientists create world's first synthetic, non-biologic vaccine

March 13, 2018
Researchers from Cardiff University have created the world's first synthetic, non-biologic vaccine.  

Engineered virus has artificial amino acid allowing it to serve as a vaccine

December 2, 2016
(Medical Xpress)—A team of researchers at Peking University has developed a new type of vaccine that they claim may allow for a new approach to generating live virus vaccines which could conceivably be adapted to any type ...

Global vaccine injury system needed to improve public health, expert argues in JAMA

February 8, 2017
A vital race is on in laboratories across the globe to develop a vaccine for the Zika virus. However, even if a vaccine were available today, many of the world's poorest people would not be able to receive it due to political ...

Recommended for you

First mouse model to mimic lung disease could speed discovery of more effective treatments

August 16, 2018
The biggest hurdle to finding effective therapies for idiopathic pulmonary fibrosis (IPF) – a life-threatening condition in which the lungs become scarred and breathing is increasingly difficult – has been the inability ...

Anticancer drug offers potential alternative to transplant for patients with liver failure

August 15, 2018
Patients suffering sudden liver failure could in the future benefit from a new treatment that could reduce the need for transplants, research published today shows.

Why do women get more migraines?

August 14, 2018
Research published today reveals a potential mechanism for migraine causation which could explain why women get more migraines than men. The study, in Frontiers in Molecular Biosciences, suggests that sex hormones affect ...

Study shows how MERS coronavirus evolves to infect different species

August 14, 2018
In the past 15 years, two outbreaks of severe respiratory disease were caused by coronaviruses transmitted from animals to humans. In 2003, SARS-CoV (severe acute respiratory syndrome coronavirus) spread from civets to infect ...

Inching closer to a soft spot in isoniazid-resistant tuberculosis

August 14, 2018
Antibiotic-resistant tuberculosis is a public health threat. TB and other bacteria become resistant to antibiotics by evolving genetic changes over time, which they can do quite quickly because bacterial lifecycles are short. ...

How long is an Ebola survivor contagious? One case is causing scientists to rethink the answer.

August 14, 2018
Surviving Ebola isn't like getting over the flu.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.